{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:06:42Z","timestamp":1793066802417,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008741","name":"EULAR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ard.2025.10.002","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T20:24:57Z","timestamp":1761769497000},"page":"61-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9683-3407","authenticated-orcid":false,"given":"Helena","family":"Marzo-Ortega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie R.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E.","family":"Fragoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xabier","family":"Michelena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mac\u00eda-Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel Z.","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andra","family":"Balanescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Bertheussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Sole","family":"Chimenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Glintborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut","family":"Kalyoncu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyorgy","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Wagenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n","family":"Queiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russka","family":"Shumnalieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique R.","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen M.G.H.","family":"van de Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Sepriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro M.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ard.2025.10.002_bib0001","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00296-020-04775-2","article-title":"Comorbidities in psoriatic arthritis: a systematic review and meta-analysis","volume":"41","author":"Gupta","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ard.2025.10.002_bib0002","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.10.002_bib0003","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3899\/jrheum.190677","article-title":"Prevalence of psoriatic arthritis patients achieving minimal disease activity in real-world studies and randomized clinical trials: systematic review with metaanalysis","volume":"47","author":"Zardin-Moraes","year":"2020","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.ard.2025.10.002_bib0004","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/rheumatology\/keaa030","article-title":"Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis","volume":"59","author":"Hag\u00e8ge","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.10.002_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152737","article-title":"Biologic switching in psoriatic arthritis: insights from real-world data and key risk factors","volume":"73","author":"Haddad","year":"2025","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2025.10.002_bib0006","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3899\/jrheum.150744","article-title":"Effectiveness and feasibility associated with switching to a second or third TNF inhibitor in psoriatic arthritis: a cohort study from southern Sweden","volume":"43","author":"Kristensen","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.10.002_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1395968","article-title":"Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12\/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database","volume":"15","author":"Strunz","year":"2024","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.ard.2025.10.002_bib0008","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1136\/ard-2022-223650","article-title":"Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries","volume":"82","author":"Glintborg","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.10.002_bib0009","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1136\/annrheumdis-2020-219535","article-title":"Response to: 'Correspondence on 'EULAR definition of difficult-to-treat rheumatoid arthritis'' by Novella-Navarro et al","volume":"82","author":"Roodenrijs","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.10.002_bib0010","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/annrheumdis-2021-220973","article-title":"EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis","volume":"81","author":"Nagy","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2025.10.002_bib0011","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41584-024-01083-y","article-title":"Difficult-to-treat psoriatic arthritis: moving out of the rheumatoid arthritis shadow","volume":"20","author":"Siebert","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.10.002_bib0012","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard-2023-225087","article-title":"Time to address the challenge of difficult to treat psoriatic arthritis: results from an international survey","volume":"83","author":"Marzo-Ortega","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2025.10.002_bib0013","doi-asserted-by":"crossref","first-page":"rkae074","DOI":"10.1093\/rap\/rkae074","article-title":"Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): a GRAPPA perspective from an international survey of healthcare professionals","volume":"8","author":"Ribeiro","year":"2024","journal-title":"Rheumatol Adv Pract"},{"issue":"1","key":"10.1016\/j.ard.2025.10.002_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003809","article-title":"Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project","volume":"10","author":"Singla","year":"2024","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.ard.2025.10.002_bib0015","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ard.2025.01.035","article-title":"The assessment of spondyloarthritis international society (ASAS) consensus-based expert definition of difficult-to-manage, including treatment-refractory, axial spondyloarthritis","volume":"84","author":"Poddubnyy","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.10.002_bib0016","unstructured":"[Updated 2025 Mar 17]. Available from: https:\/\/www.eular.org\/recommendations\/points-to-consider-task-forces-project-applications"},{"key":"10.1016\/j.ard.2025.10.002_bib0017","doi-asserted-by":"crossref","unstructured":"Harrison SR, Fragoulis G, Michelena X, et al. Prevalence, outcomes, and predictive factors: a systematic literature review to inform the development of EULAR Points to Consider for the definition of Difficult-to-Manage and Treatment-Refractory psoriatic arthritis. In press, ERO 2025. doi: 10.1016\/j.ero.2025.07.007","DOI":"10.1016\/j.ero.2025.07.007"},{"key":"10.1016\/j.ard.2025.10.002_bib0018","unstructured":"Chalmers I, Glasziou P, Greenhalgh T, et al. The Oxford levels of evidence 2. In: Oxford Centre for Evidence-Base Medicine [updated 2025 Jun 21]. Available from:https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence."},{"key":"10.1016\/j.ard.2025.10.002_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000880","article-title":"Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry","volume":"5","author":"Mease","year":"2019","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.ard.2025.10.002_bib0020","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/annrheumdis-2018-214140","article-title":"Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries","volume":"78","author":"Gorlier","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.10.002_bib0021","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s10067-023-06850-y","article-title":"Similar levels of disease activity and remission rates in patients with psoriatic arthritis and rheumatoid arthritis-results from the Finnish quality register","volume":"43","author":"Weman","year":"2024","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.10.002_bib0022","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40744-021-00286-z","article-title":"Real-world treatment persistence with biologic disease-modifying antirheumatic drugs among German patients with psoriatic arthritis-a retrospective database study","volume":"8","author":"Sewerin","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.ard.2025.10.002_bib0023","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/rheumatology\/kez427","article-title":"Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA","volume":"59","author":"Brahe","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.10.002_bib0024","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/art.37876","article-title":"Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor \u03b1 inhibitor therapy: results from the Danish nationwide DANBIO registry","volume":"65","author":"Glintborg","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.10.002_bib0025","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/annrheumdis-2018-eular.4374","article-title":"THU0292 Diagnostic experiences of patients with psoriatic arthritis: misdiagnosis is common","volume":"77","author":"Ogdie","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.10.002_bib0026","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000656","article-title":"Distinguishing rheumatoid arthritis from psoriatic arthritis","volume":"4","author":"Merola","year":"2018","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ard.2025.10.002_bib0027","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.10.002_bib0028","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s41927-018-0030-y","article-title":"Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients' health-related quality of life and productivity","volume":"2","author":"Coates","year":"2018","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.ard.2025.10.002_bib0029","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13075-019-1811-4","article-title":"Time to minimal disease activity in relation to quality of life, productivity, and radiographic damage 1 year after diagnosis in psoriatic arthritis","volume":"21","author":"Wervers","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2025.10.002_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002706","article-title":"Importance of quick attainment of minimal disease activity for a positive impact on lives of patients with psoriatic arthritis","volume":"8","author":"Snoeck Henkemans","year":"2022","journal-title":"RMD Open"},{"issue":"11","key":"10.1016\/j.ard.2025.10.002_bib0031","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/acr2.11714","article-title":"Association between achievement of clinical disease control and improvement in patient-reported outcomes and quality of life in patients with psoriatic arthritis in the phase 3 SELECT-PsA 1 and 2 randomized controlled trials","volume":"6","author":"Kavanaugh","year":"2024","journal-title":"ACR Open Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2025.10.002_bib0032","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.semarthrit.2020.03.015","article-title":"Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study","volume":"50","author":"Coates","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2025.10.002_bib0033","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13075-021-02474-2","article-title":"Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib","volume":"23","author":"Coates","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.ard.2025.10.002_bib0034","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/acr.23333","article-title":"Impact of comorbidities on tumor necrosis factor inhibitor therapy in psoriatic arthritis: a population-based cohort study","volume":"70","author":"Ballegaard","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ard.2025.10.002_bib0035","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/rheumatology\/ken090","article-title":"Cardiovascular risk profile of patients with psoriatic arthritis compared to controls\u2014the role of inflammation","volume":"47","author":"Tam","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.10.002_bib0036","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2011-200567","article-title":"Cardiovascular and metabolic risks in psoriasis and psoriatic arthritis: pragmatic clinical management based on available evidence","volume":"71","author":"Johnsson","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ard.2025.10.002_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152165","article-title":"Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review","volume":"59","author":"Torosian","year":"2023","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.ard.2025.10.002_bib0038","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00296-021-04925-0","article-title":"Fibromyalgia influences health-related quality of life and disease activity in psoriatic arthritis","volume":"42","author":"Kancharla","year":"2022","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.ard.2025.10.002_bib0039","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/1756-185X.13987","article-title":"Fibromyalgia in patients with psoriatic arthritis: impact on disease activity indices, fatigue and health-related quality of life","volume":"24","author":"Elsawy","year":"2021","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.10.002_bib0040","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10067-019-04734-8","article-title":"Systematic review of mental health comorbidities in psoriatic arthritis","volume":"39","author":"Zhao","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.10.002_bib0041","first-page":"159","article-title":"Depression and anxiety in a real-world psoriatic arthritis longitudinal study: should we focus more on patients' perception?","volume":"41","author":"Gialouri","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ard.2025.10.002_bib0042","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.ard.2025.10.002_bib0043","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40266-024-01136-7","article-title":"Real-world drug survival of biologics and targeted synthetic disease-modifying anti-rheumatic drugs among patients with psoriatic arthritis","volume":"41","author":"Rosenberg","year":"2024","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ard.2025.10.002_bib0044","first-page":"191","article-title":"Drug utilization and medication adherence for the treatment of psoriatic arthritis: an Italian study","volume":"11","author":"Santoleri","year":"2024","journal-title":"Glob Reg Health Technol Assess"},{"issue":"3","key":"10.1016\/j.ard.2025.10.002_bib0045","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/annrheumdis-2020-216999","article-title":"Use of multidimensional composite scores in rheumatology: parsimony versus subtlety","volume":"80","author":"Landewe","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ard.2025.10.002_bib0046","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/rheumatology\/keaa062","article-title":"Prevalence of extra-articular manifestations in psoriatic arthritis: a systematic review and meta-analysis","volume":"59","author":"Pittam","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.ard.2025.10.002_bib0047","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/rheumatology\/kead225","article-title":"Diagnostic delay is associated with uveitis and inflammatory bowel disease in AS: a study of extra-musculoskeletal manifestations in SpA","volume":"63","author":"Michelena","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.ard.2025.10.002_bib0048","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"5","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ard.2025.10.002_bib0049","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.19509","article-title":"A head-to-head comparison of Ixekizumab vs guselkumab in patients with moderate to severe plaque psoriasis: 24 week efficacy and safety results from a randomised, double-blinded trial","volume":"184","author":"Blauvet","year":"2021","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.ard.2025.10.002_bib0050","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2022.2133533","article-title":"Systematic review of TNF\u03b1-induced paradoxical psoriasis: treatment outcomes of switching to alternative biologic therapies in inflammatory bowel disease patients","volume":"34","author":"Revankar","year":"2023","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.ard.2025.10.002_bib0051","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/rheumatology\/keaa598","article-title":"Improving patient care through a collaborative effort in the Leeds combined psoriatic service: an effective provision of multi-specialty input","volume":"60","author":"Vandevelde","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.10.002_bib0052","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fmed.2020.00487","article-title":"Ultrasound imaging in psoriatic arthritis: what have we learnt in the last five years?","volume":"7","author":"Dubash","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"10.1016\/j.ard.2025.10.002_bib0053","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.clinthera.2023.07.017","article-title":"Utility of musculoskeletal ultrasound in psoriatic arthritis","volume":"45","author":"Hum","year":"2023","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.ard.2025.10.002_bib0054","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13244-021-01035-0","article-title":"Role of diagnostic imaging in psoriatic arthritis: how, when, and why","volume":"12","author":"Crespo-Rodr\u00edguez","year":"2021","journal-title":"Insights Imaging"},{"issue":"4","key":"10.1016\/j.ard.2025.10.002_bib0055","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/2475530320963196","article-title":"Patient\u2013physician alignment in satisfaction with psoriatic arthritis treatment: analysis from a cross-sectional survey in the United States and Europe","volume":"5","author":"Gossec","year":"2020","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"6","key":"10.1016\/j.ard.2025.10.002_bib0056","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s10067-019-04870-1","article-title":"Physician-patient alignment in satisfaction with psoriatic arthritis treatment in Latin America","volume":"39","author":"Soriano","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2025.10.002_bib0057","article-title":"P179 Shared decision-making in psoriatic arthritis consultations","volume":"62","author":"Watson","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.ard.2025.10.002_bib0058","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.reuma.2019.06.003","article-title":"Is obesity a predictor for lack of response to treatment in psoriatic arthritis? A systematic review","volume":"17","author":"Gratac\u00f3s","year":"2021","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"10.1016\/j.ard.2025.10.002_bib0059","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/art.42780","article-title":"Difficult-to-treat psoriatic arthritis: a conceptual approach","volume":"76","author":"Fagni","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.10.002_bib0060","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1136\/annrheumdis-2014-205389","article-title":"Association between tobacco smoking and response to tumour necrosis factor \u03b1 inhibitor treatment in psoriatic arthritis: results from the DANBIO registry","volume":"74","author":"H\u00f8jgaard","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ard.2025.10.002_bib0061","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard-2023-224148","article-title":"EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis","volume":"82","author":"Zabotti","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ard.2025.10.002_bib0062","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1093\/rheumatology\/keae005","article-title":"Exploring the unifying concept of spondyloarthritis: a latent class analysis of the REGISPONSER registry","volume":"63","author":"Michelena","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.10.002_bib0063","article-title":"Characteristics of difficult-to-treat psoriatic arthritis: a comparative analysis","volume":"46","author":"Philippoteaux","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.10.002_bib0064","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1093\/rheumatology\/keae263","article-title":"Identification and characteristics of patients with potential difficult-to-treat psoriatic arthritis: exploratory analyses of the Greek PsA registry","volume":"63","author":"Vassilakis","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.10.002_bib0065","article-title":"The mediating role of shared decision making in the effect of the patient-physician relationship on compliance with treatment","volume":"8","author":"Deniz","year":"2021","journal-title":"J Patient Exp"},{"issue":"4","key":"10.1016\/j.ard.2025.10.002_bib0066","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/art.38995","article-title":"Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis","volume":"67","author":"Belasco","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2025.10.002_bib0067","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.3390\/ijms24054901","article-title":"Psoriatic arthritis: pathogenesis and targeted therapies","volume":"24","author":"Azuaga","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.ard.2025.10.002_bib0068","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/annrheumdis-2020-218186","article-title":"IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors","volume":"80","author":"Nerviani","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.10.002_bib0069","article-title":"No significant effects of IL-23 on initiating and perpetuating the axial spondyloarthritis: the reasons for the failure of IL-23 inhibitors","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ard.2025.10.002_bib0070","article-title":"Comparative immunology of entheseal anchorage sites between spine, hip and knee demonstrates up to 70-fold greater IL-23 induction from axial enthesis bone: a new angle on the failure of IL-23 blockade in ankylosing spondylitis [abstract]","author":"Harland","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2025.10.002_bib0071","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1093\/rheumatology\/keae577","article-title":"68Ga-FAPI and 18F-NaF PET\/CT in psoriatic arthritis: a comparative study","volume":"64","author":"Yang","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.ard.2025.10.002_bib0072","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004294","article-title":"Anatomical pattern of entheseal and synovial fibroblast activation in patients with psoriasis and its risk of developing psoriatic arthritis","volume":"10","author":"Corte","year":"2024","journal-title":"RMD Open"},{"issue":"8","key":"10.1016\/j.ard.2025.10.002_bib0073","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1093\/rheumatology\/keac676","article-title":"The top 10 research priorities in psoriatic arthritis: a James Lind Alliance Priority Setting Partnership","volume":"62","author":"Hailey","year":"2023","journal-title":"Rheumatology (Oxford)."}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725044334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725044334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T04:09:19Z","timestamp":1773893359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725044334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0003496725044334"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.10.002","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2025.07.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}